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Abstract
Adenovirus-mediated delivery of the immune-stimulatory cytokine Flt3L and the conditionally cytotoxic thymidine kinase (TK)
induces tumor regression and long-term survival in preclinical glioma (glioblastoma multiforme [GBM]) models. Flt3L induces
expansion and recruitment of plasmacytoid dendritic cells (pDCs) into the brain. Although pDCs can present antigen and pro-
duce powerful inflammatory cytokines, that is, interferon α (IFN-α), their role in tumor immunology remains debated. Thus, we
studied the role of pDCs and IFN-α in Ad.TK/GCV+ Ad.Flt3L–mediated anti-GBM therapeutic efficacy. Our data indicate that the
combined gene therapy induced recruitment of plasmacytoid DCs (pDCs) into the tumor mass; which were capable of in vivo
phagocytosis, IFN-α release, and T-cell priming. Thus, we next used either pDCs or an Ad vector encoding IFN-α deliveredwithin
the tumor microenvironment. When rats were treated with Ad.TK/GCV in combination with pDCs or Ad-IFN-α, they exhibited
35% and 50% survival, respectively. However, whereas intracranial administration of Ad.TK/GCV + Ad.Flt3L exhibited a high
safety profile, Ad-IFN-α led to severe local inflammation, with neurologic and systemic adverse effects. To elucidatewhether the
efficacy of the immunotherapywas dependent on IFN-α–secreting pDCs, we administered an Ad vector encoding B18R, an IFN-
α antagonist, which abrogated the antitumoral effect of Ad.TK/GCV+Ad.Flt3L. Our data suggest that IFN-α release by activated
pDCs plays a critical role in the antitumor effect mediated by Ad.TK/GCV + Ad.Flt3L. In summary, taken together, our results
demonstrate that pDCs mediate anti-GBM therapeutic efficacy through the production of IFN-α, thus manipulation of pDCs
constitutes an attractive new therapeutic target for the treatment of GBM.
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Introduction
Glioblastoma multiforme (GBM) is the most common and aggressive
primary brain tumor. Its invasiveness in the surrounding nonneoplastic
brain and its intrinsic resistance to traditional therapeutic approaches
make this disease a therapeutic challenge [1–4]. Several therapeutic
approaches have attempted to stimulate the immune system to target
and kill GBM cells. To this end, interferon α (IFN-α) has recently been
proposed for the treatment of GBM owing to its effects on antitumor
immunity, angiogenesis, and tumor cell proliferation and death [5–8].
IFN-α has shown a direct antitumor effect by reducing angiogenesis in
GBM growing in the rat brain [7], inhibiting the proliferation of GBM
cells [9] and sensitizing them to proapoptotic agents [10]. IFN-α has also
shown indirect antitumor activity in several types of cancers through the
stimulation of the host immune system: it can activate dendritic cells
(DCs), upregulate major histocompatibility complex (MHC) types I
and II expression, increase the recruitment of immune cells into the
tumor microenvironment, and enhance cellular and humoral antitumor
immunity [6]. Although IFN-α was the first cytokine to be approved for
cancer treatment, its considerable toxicity has limited its use [11,12].
Our efforts toward developing an immunotherapeutic approach for
the treatment of GBM that would be highly effective and nontoxic to
the surrounding brain parenchyma consist of the delivery of a conditional
cytotoxic molecule and a cytokine using adenoviral vectors (Ads) [13–16].
One Ad encodes Herpes simplex virus 1 thymidine kinase (Ad.TK), which
kills proliferating cells in the presence of ganciclovir, and the second
Ad encodes fms-like tyrosine kinase 3 ligand (Ad.Flt3L), which recruits
antigen-presenting cells (APCs) to the brain tumor microenvironment
[17]. This combined gene therapy eradicates established intracranial
tumors in several rat and mouse preclinical GBMmodels [18].We have
previously shown that this treatment induces an antitumor immune re-
sponse that is dependent on APCs, CD4+, and CD8+ T cells [14,19,20].
Flt3L is a growth factor that induces the expansion of DCs [21].
Our previous results have shown that intracranial administration of
an Ad encoding Flt3L (Ad.Flt3L) induces the expansion and recruit-
ment of plasmacytoid DCs (pDCs), which are a subset of IFN-α–
producing DCs, into the rat brain parenchyma [22]. The role of pDCs
in tumor immunology remains debated because it has been reported
that pDCs can induce immunologic tolerance or antitumor immunity
[23]. In patients with head and neck squamous cell carcinoma, tumor-
infiltrating pDCs were found to have a decreased response to Toll-like
receptor 9 (TLR9) activation [24]. pDCs detected in ovarian cancer
were involved in the generation of an immunosuppressive tumor micro-
environment [25] and the promotion of tumor angiogenesis [26].
pDCs can mature and express costimulatory molecules and inflam-
matory cytokines and migrate to the draining lymph nodes (dLNs) to
present tumor antigens to naive CD4+ T cells [23]. Although there
is evidence that pDCs have the ability to present antigens, their main
role seems to be as IFN-α–producing cells [27]. pDCs are considered
the professional IFN-α–producing cells, being able to release between
100 to 1000 times more type I IFN than other immune cells after
activation [27]. Here we aimed to elucidate the role of pDCs in the
antitumor immune response mediated by Ad.TK + Ad.Flt3L. Thus,
we assessed the ability of intratumoral pDCs to uptake and transport
tumor cell remnants. We also purified tumor-infiltrating pDCs and
characterized the expression of costimulatory molecules and their ability
to prime T cells and produce inflammatory cytokines.
Because here we demonstrate that treatment with Ad.TK + Ad.Flt3L
induces the recruitment of IFN-α–producing pDCs into the brain
tumor mass, we hypothesized that this cytokine could play a critical
role in mediating the antitumor therapeutic efficacy elicited by this
treatment. Our data suggest that IFN-α release by activated pDCs
mediates antitumor effects elicited by Ad.TK/GCV + Ad.Flt3L gene
therapy. Therefore, manipulation of pDCs constitutes an attractive
novel target for the treatment of GBM.
Materials and Methods
Adenoviral Vectors
The vectors used in this study were first-generation, replication-
deficient, recombinant adenovirus type 5 vectors (Ad), with deletion
in the E1 and E3 regions; the expression cassette containing the appro-
priate transgene is inserted within the E1 region [28]. Five Ad vectors
were used: Ad.TK (encodes HSV1-thymidine kinase under the control
of the human CMV promoter [14,19]), Ad.Flt3L (encodes human
soluble fms-like tyrosine kinase ligand under the control of the human
CMV promoter [14,17,19,22,29]), Ad.IFN-α (kindly donated by
Dr Kazunori Aoki, National Cancer Center Research Institute, Tokyo,
Japan; it encodes rat IFN-α under the control of the CAG promoter,
which combines the human cytomegalovirus immediate-early enhancer
and a modified chicken β-actin promoter [30]), Ad.B18R (encodes
B18R an IFN-α decoy receptor under the control of the murine CMV
promoter [31]), and, as a control, we used an Ad without transgene
(Ad.0 [14]). For the generation of Ad.B18R, the B18R gene was poly-
merase chain reaction amplified from purified Vaccinia viral DNA (kind
gift from Dr R Mark L. Buller, Saint Luis University, MO [31]) using
the following primers: B18R-for ccgctcgaggatatcgtcgacATGAGTC-
GTCGTCTGATT (5′ overhangs containing XhoI, EcoRV, and SalI
restriction sites) and B18R-rev ccgctcgaggactagtgtcgacCTATACTT-
TGGTAGGTGG (3′ overhangs containing XhoI, SpeI, and SalI restric-
tion sites). Thirty thermal cycles (94°C denature, 55°C anneal, 72°C
extension) were performed using an Applied Biosystems thermocycler
(Foster City, CA). The polymerase chain reaction product was puri-
fied (Qiagen, Hilden, Germany) and cloned into pGEM-T-easy vector
(Promega, Madison, WI). The B18R gene was excised with XhoI and
cloned into the SalI site of pAL120, an adenoviral shuttle plasmid con-
taining the powerful murine CMV promoter in the E1 region
of adenovirus [32] to generate pAL120-B18R. 293 cells were co-
transfected with pAL120-B18R and pJM17 (Microbix, Toronto, Canada)
using TransIT-293 Transfection Reagent (Mirus Bio, Madison, WI)
to rescue the viral vector. Ad-mCMV-B18R was amplified and puri-
fied as described by us previously [28]. All viral preparations were tested
free of replication-competent adenovirus and lipopolysaccharide con-
tamination using methods previously described [28].
Rat GBM Model
Rats were housed in a pathogen-free environment and humidity
and temperature–controlled vivarium on a 12:12-hour light/dark
cycle (lights on 7:00 A.M.) with free access to food and water. All animal
experiments were performed after prior approval by the Institutional
Animal Care and Use Committee at Cedars-Sinai Medical Center
and conformed to the policies and procedures of the Comparative
Medicine Department. After administration of anesthesia, animals were
placed in a stereotactic apparatus and injected unilaterally into the
right striatum. Rats were injected using a 10-μl Hamilton syringe
(coordinates: 1 mm forward from bregma and 3.1 mm lateral). Animals
were allowed to recover, and their health status was closely moni-
tored. CNS-1 cells (4500) were injected as described before [33].
CNS-1 cells were grown in Dulbecco modified Eagle culture medium
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(CellGro, Herndon, VA), supplemented with 10% fetal calf serum, 1%
L-glutamine, 1% Pen-Strep, 1% nonessential amino acids, and passaged
routinely. On the day of surgery, cells were trypsinized, resuspended in
Dulbecco modified Eagle medium without supplements (1500 cells/μl)
and kept on ice for up to 2 hours.
Ad vectors were administered 10 days after tumor implantation at a
dose of 5 × 107 each in a volume of 3 μl, using the same drill hole and
delivered in three locations ventral of the dura: 5.5, 5.0, and 4.5 mm
into the tumor mass (1 μl per site). The total viral load in each injec-
tion was standardized by the addition of Ad.0 when single viruses were
administered (total dose, 108 pfu). Twenty-four hours after delivery of
viral vectors, animals that received Ad.TK began treatment with GCV
(7 mg/100 μl intraperitoneally), twice daily for 7 days. Animals were
monitored daily and killed according to the guidelines of the Institu-
tional Animal Care and Use Committee at Cedars-Sinai Medical Cen-
ter at the first signs of moribund behavior or at predetermined time
points for collection of tumor-infiltrating immune cells, immuno-
fluorescence, or neuropathology. Animals were killed under deep
anesthesia by terminal perfusion with Tyrodes solution (132mMNaCl,
1.8 mM CaCl2, 0.32 mM NaH2PO4, 5.56 mM glucose, 11.6 mM
NaHCO3, and 2.68 mM KCl) followed by perfusion with 4%
paraformaldehyde (PFA) when tissues were to be used for immuno-
fluorescence or neuropathology. Brains were removed and further fixed
in 4% PFA for 4 to 5 days or processed for flow cytometry.
A set of tumor-bearing rats was injected with 2 × 107 yellow-green
FluoSpheres (1 μm; catalog no. F-13081; Molecular Probes, Eugene,
OR) in a total volume of 4 μl (1 μl each delivered at four locations ventral
to the dura: −5.25, −4.75, −4.25, and −3.75) 3 days after the treatment
with Ad.TK + Ad.Flt3L. Rats were killed 2 and 5 days later and the
brains and cervical lymph nodes were collected to detect phagocytic
activity in vivo. Brains and cervical lymph nodes were collected and
postfixed for 72 hours. A set of naive rats was injected with the Ad
vectors in the brain as described above for neuropathologic analysis.
They were weighted daily and killed 7 and 60 days after injection.
Identification of Tumor-Infiltrating Immune Cells
At 5 and 12 days after treatment, brains from tumor-bearing rats
were carefully separated from the meninges with scissors and removed
from the skull. Tumors were carefully dissected with a scalpel blade and
removed avoiding the ventricles. The tumor tissue was diced with a
razor blade before homogenizing in supplemented RPMI medium
(containing 10% fetal bovine serum, 1% penicillin/streptomycin (PS),
1% L-glutamine) using a glass Tenbroeck homogenizer (Kontes, Vineland,
NJ). Mononuclear cells were purified from brain tissue by centrifuga-
tion (2200 rpm) through a Percoll step gradient (70% to 30% Percoll
in phosphate-buffered saline [PBS]) for 20 minutes in 15-ml falcon
tubes (GE Healthcare, Piscataway, NJ); mononuclear cells migrate to
the interface between 30% and 70% Percoll. The mononuclear cells on
the interphase were removed into 10-ml fresh medium, washed, and
counted using Trypan blue. Tumor-infiltrating immune cells were
labeled with antibodies in cell surface staining buffer (0.1 M PBS,
without Ca2+ and Mg2+, with 1% fetal bovine serum) for analysis by
flow cytometry using a FACScan flow cytometer (Becton Dickinson,
San Jose, CA). To identify the immune cell populations, we used the
following antibodies (BD Biosciences, San Diego, CA): pDCs and B cells
were detected by labeling with mouse antirat CD3-FITC, mouse antirat
CD4-PECy5, and mouse antirat CD45R-PE (catalog nos. 559975,
554839 and 554881, respectively; BD Pharmingen). NK, NK-T, and
T cells were detected by labeling with mouse antirat CD3-FITC and
mouse antirat CD161a-PE (catalog nos. 559975 and 555006, respec-
tively; BD Pharmingen). Macrophages were detected by labeling with
mouse antirat CD68.ED1-Alexa488 (catalog no. MCA341A488;
Serotec, Oxford, United Kingdom) after 4% paraformaldehyde fixa-
tion. Microglia was identified by labeling with mouse antirat CD45-
PE (catalog no. 554878; BD Pharmingen). Conventional DCs (cDCs)
were detected by labeling with mouse antirat CD11c-FITC (catalog no.
MCA1441F; Serotec), MHC II–PerCP and CD45-PE (catalog nos.
557016 and 554878; BDPharmingen). In all instances, tumor-infiltrating
populations were determined based on gating established with naive
splenic populations. Spleens were harvested and homogenized in glass
Tenbroeck homogenizer. Red blood cells were removed by incubating
in 3 ml of ACK solution (0.15 mM NH4Cl, 10 mM KHCO3, and
0.1 mM sodium EDTA at pH 7.2) for 3 minutes on ice. Splenocytes
were then washed in supplemented RPMI medium and processed in
parallel with tumor-infiltrating immune cells for flow cytometry as de-
scribed above. Data were analyzed using DAKO Summit v4.3 software
(Dako Cytomation, Cambridge, United Kingdom).
Characterization of Tumor-Infiltrating pDCs
Five days after the treatment with Ad.TK/GCV + Ad.Flt3L tumor-
infiltrating pDCs were collected by Percoll gradient as described above,
followed by staining with mouse antirat CD3-FITC, mouse antirat CD4-
PeCy5, and mouse antirat CD45R-PE (see above) and purification by
fluorescent-assisted cell sorting using an Ario Cell Sorter (Dako Cytoma-
tion). CD3−/CD45R+/CD4+ cells were then characterized as follows:
Expression of activation markers. We assessed the expression of
activation markers in tumor-infiltrating pDCs by flow cytometry
using mouse antirat CD86 and mouse antirat MHC II–FITC (catalog
nos. 555018 and 554928; BD Pharmingen). Spleen pDCs activated
with 50 μg/ml ODN CpG2216 (catalog no. ALX-746-005; Axxora
LLC, San Diego, CA) for 24 hours were used as positive control.
MHC II immunofluorescence. After 24 hours of incubation with
50 μg/ml ODN, CpG2216 tumor-infiltrating pDCs were fixed with
4% PFA for 20 minutes on ice. Cells were stained with mouse antirat
MHC II (catalog no. MCA46GA; Serotec). Cytoskeleton was stained
with phalloidin–Alexa 594 (1:200, catalog no. A12381; Molecular
Probes) for 20 minutes at room temperature. Nuclei were stained with
4′, 6-diamidino-2-phenylindole (DAPI, 5 μg/ml, catalog no. D21490;
Invitrogen Molecular Probes). Cells were loaded onto rounded cover-
slips, dried at room temperature for 24 hours and mounted with
ProLong Antifade (Invitrogen Molecular Probes). We determined the
percentage of pDCs containing beads by microscopy. We used spleen
pDCs incubated 24 hours with ODN CpG2216 as positive control.
ELISA. Levels of interleukin 6 (IL-6) and tumor necrosis factor α
(TNF-α) in conditioned media from tumor-infiltrating pDCs incu-
bated with 50 μg/ml CpG2216 for 24 hours were determined by ELISA
following the manufacturer’s protocol (catalog no. ER2IL6 [Endogen
Searchlight, Boston, MA] and catalog no. 88-7340 [eBiosciences,
San Diego, CA], respectively). Absorbance was read on a 96-well plate
reader (SpectraMax Plus; Molecular Devices, Sunnyvale, CA) at 450 and
570 nm to subtract background. Spleen pDCs incubated for 24 hours
with ODN CpG2216 were used as a positive control.
Biologic assay for IFN-α detection. IFN-α content was assessed
in serum collected from naive rats 7 days after intracranial injection
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of Ad.IFN-α, in conditioned medium from activated tumor-infiltrating
pDCs and in conditioned medium from COS7 cells that were infected
with Ad.IFN-α (200 pfu/cell) alone or in combination with Ad.B18R
(100 infectious units/cell) for 48 hours. To perform IFN-α detec-
tion CNS-1 cells were transfected with 40 ng of an interferon-sensitive
response element (pISRE) linked to firefly luciferase (Clontech, Moun-
tain View, CA) and 4 ng of constitutive expressed renilla luciferase
(as internal control). After 24 hours, transfected CNS-1 cells were
incubated in the presence of recombinant IFN-α (1000 U/ml, posi-
tive control, catalog no. 13100-1; R&D Systems, Minneapolis, MN),
serum or conditioned medium for 6 hours. Firefly and renilla luciferase
were detected using the Dual Luciferase Reporter Assay system
(Promega) and a Veritas luminometer (Turner Biosystems, Sunnyvale,
CA) per the manufacturer’s instructions.
T-cell priming (mixed leukocyte reaction). Five days after the treat-
ment with Ad.TK/GCV + Ad.Flt3L, tumor-infiltrating pDCs were
purified from 20 rats as described above. T cells were concurrently puri-
fied from the spleen of allogeneic-naive C57/BL6 mouse by magnetic
activated cell sorting after labeling with CD4 and CD8 magnetic beads
(Miltenyi Biotec, Bergisch-Gladbach, Germany) as previously described
[17]. Purified T cells were labeled with 5 μM CFDA-SE (Molecular
Probes) per the manufacturer’s instructions. A total of 20,000 labeled
mouse T cells were incubated with increasing numbers of unlabeled
tumor-infiltrating pDCs (0 to 20,000). Cells were incubated in X-Vivo
10 media (Cambrex, Walkersville, MD) for 5 days and subsequently
analyzed by flow cytometry gating mouse T cells with a specific anti-
mouse CD45 antibody (R&D Systems).
Bead Uptake In Vivo
Two and five days after the administration of beads, brains and cer-
vical lymph nodes were collected and postfixed for 72 hours. Brains
were sectioned with a vibratome into 60-μm serial coronal sections.
The lymph nodes were cryoprotected for 24 hours in a phosphate-
buffered 20% sucrose solution, frozen in Tissue-Tek OCT compound
on dry ice, and sectioned with a cryostat into 30-μm sections. Immuno-
fluorescence staining was performed as previously described [14,34]
on the brain and lymph node sections. Macrophages and activated
microglia were identified by mouse antirat CD68 (1:500; MCA341R;
Serotec) and rabbit antirat Iba-1 (1:500; 019-19741; WAKO, Osaka,
Japan). pDCs were identified by monoclonal antibodies against CD45R
(1:100; IgG2b, 554879; BD Biosciences) and CD4 (1:100; IgG2a,
550296; BD). cDCs were identified by mouse antirat DC antibody
OX-62 (1:100, 555010; BD). Alexa Fluor secondary antibodies
(1:1000; Molecular Probes) were used: goat antimouse IgG 594
(A11032), goat antirabbit IgG 647 (A21245), goat antimouse IgG2a
594 (A21135), and goat antimouse IgG2b 647 (A21242). Nuclei were
stained with DAPI (5 μg/ml; Invitrogen Molecular Probes); cells and
tissues were mounted with ProLong Antifade (Invitrogen Molecular
Probes). Confocal micrographs were obtained using a Leica confocal
microscope TCS SP2 with AOBS equipped with 405-nm violet-diode
UV laser, 488-nm argon laser, and 594- and 633-nm helium-neon la-
sers and using a HCX PL APO 63× 1.4 numerical aperture oil objective
(Leica Microsystems Heidelberg, Mannheim, Germany).
Neuropathology
Neuropathologic analysis was performed in the brain of rats that
underwent tumor regression and in naive rat brain 7 and 60 days
after injecting Ad.IFN-α alone or in combination with Ad.TK. After
perfusion with Tyrode solution and 4% PFA, brains were fixed in
4% paraformaldehyde for three additional days. Sixty-micrometer
serial coronal sections were cut through the striatum, and free-floating
immunocytochemistry was performed as previously described [14].
Briefly, endogenous peroxidases were inactivated with 0.3% hydrogen
peroxide, followed by blocking in 10% horse serum/PBS. Sections
were incubated for 72 hours with the following antibodies: anti–
tyrosine hydroxylase (TH) in rabbit (1:5000, no. 657012; Calbiochem,
La Jolla, CA), anti–myelin basic protein (MBP) in mouse (1:1000,
no. MAB1580; Chemicon, Temecula, CA), antirat CD68 in mouse
(clone ED1 to identify macrophages/activated microglia; 1:1000,
no. MCA341R; Serotec), antirat major histocompatibility complex II
(MHC II, 1:1,000, no. MCA46GA; Serotec), and antirat CD8α (to iden-
tify cytotoxic T cells; 1:1000, no. MCA48G; Serotec). Then, the sections
were incubated for 4 hours with biotin-conjugated antirabbit goat IgG or
antimouse rabbit IgG (1:800, nos. E0432 and E0464, respectively;
DAKO, Glostrup, Denmark). Binding of biotinylated secondary anti-
bodies was detected using the Vectastain Elite ABC horseradish peroxidase
method (Vector Laboratories, Burlingame, CA) followed by the glucose
oxidase and nickel ammonium sulfate–intensified diaminobenzidine
method. Sectionsweremounted on gelatinized glass slides and dehydrated
through graded ethanol solutions and coverslipped using DPX mount-
ing medium for histology (Sigma, St Louis, MO).
Nissl staining was used to determine the histopathologic features of
the brains. Briefly, brain sections were mounted on gelatinized glass
slides and incubated in cresyl violet (0.1%; Sigma). Sections were
passed through destain solution (70% ethanol, 10% acetic acid), de-
hydrated (100% ethanol and xylene), and coverslipped using DPX
mounting medium for histology.
Tissues were photographed with Carl Zeiss Optical Axioplan micro-
scope using AxioVision Rel 4.6 and MOSAIX software (Carl Zeiss,
Chester, VA).
Statistical Analysis
Sample sizes were calculated to detect differences between groups with
a power of 80% at a 0.05 significance level using PASS 2008 (Power
and sample size software; NCSS, Kaysville, UT). Kaplan-Meier survival
curves were analyzed using theMantel log rank (GraphPad Prism version
3.00; GraphPad Software, San Diego, CA). Flow cytometry, phago-
cytosis, and ELISA data were analyzed by analysis of variance (ANOVA;
NCSS). When data failed normality or Levene test for variance homo-
geneity, they were log transformed. Randomization test was used to
analyze body weight curves (NCSS). P < .05 was used to determine
the null hypothesis to be invalid. The statistical tests used are indicated
in the figure legends.
Results
Recruitment of Tumor-Infiltrating Immune Cells into the Tumor
Microenvironment in Response to Intratumoral Expression of
TK and Flt3L in a Syngeneic, Orthotopic Rat GBM Model
Our previous results showed that intratumoral administration of
Ad.TK + Ad.Flt3L triggers an antitumor immune response that leads
to tumor regression and long-term survival in ∼70% of rats bearing
intracranial syngeneic GBM [14,19,35]. In the present work, we aimed
to identify which immune cells are recruited within the tumor micro-
environment in response to this therapeutic approach. Lewis rats were
implanted in the brain with syngeneic CNS-1 cells, and 10 days later,
they were treated with an intratumoral injection of Ad.TK + Ad.Flt3L,
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saline, or an empty Ad (Ad.0), as controls. At 5 and 12 days after
the treatment, mononuclear cells were purified from the tumors and
analyzed by flow cytometry (Figure 1). We found that treatment with
Ad.TK + Ad.Flt3L induced recruitment of APCs into the brain tumor
mass. Although macrophages and cDCs were readily detected within
the tumor of control rats, treatment with Ad.TK + Ad.Flt3L increased
approximately three-fold the infiltration levels of these cells into the
tumor microenvironment. However, pDCs were found only in the
brain tumor of Ad.TK + Ad.Flt3L-treated rats and were virtually absent
in control animals treated with saline or Ad.0. The levels of microglial
cells remained unchanged after treatment with saline, Ad.0, or Ad.TK +
Ad.Flt3L at both time points. We also observed that NK cells were in-
creased three-fold in the tumor mass 5 days after treatment with Ad.TK +
Ad.Flt3L. B lymphocytes were virtually absent in the tumor of control-
treated rats and were recruited into the tumor microenvironment in
response to the combined gene therapy 12 days after the treatment.
T cells were elevated in the tumors treated with Ad.0 and Ad.TK +
Ad.Flt3L, when compared with saline-treated control rats.
Tumor-Infiltrating pDCs Exhibit an Immature Phenotype
and Are Capable of T-cell Priming
The role of pDCs in brain tumor immunology remains debated
[23,36]. Also, it is not clear whether these cells play a role in the pro-
cess of antigen uptake and presentation during the onset of immune
responses or they only act as IFN type I–producing cells [27]. We char-
acterized tumor-infiltrating pDCs recruited in response to Ad.TK + Ad.
Flt3L treatment. Five days after treatment, immune cells were collected
and pooled from the tumors (n = 25), and pDCs were purified by
FACS (CD3−/CD45R+/CD4+; Figure 2A). To determine the activa-
tion status of tumor-infiltrating pDCs, we assessed the expression levels
of activation markers, their capability of releasing cytokines, as well as
their ability to become activated in response to TLR9 agonist CpG2216.
The levels of expression of MHC II and CD86 were determined by
flow cytometry, using spleen pDCs activated with CpG2216 as posi-
tive controls. We found that tumor-infiltrating pDCs expressed very
low levels MHC II and CD86, when compared with activated spleen
pDCs (Figure 2B), suggesting that pDCs within the brain tumor micro-
environment exhibit an immature phenotype. Tumor pDCs were
then activated in vitro by incubating with TLR9 agonist CpG2216 for
24 hours. Cytokine release was assessed by ELISA (Figure 2C ), and
expression of MHC II was assessed by immunostaining (Figure 2D),
using spleen pDCs as positive controls. We found that tumor pDCs
can be readily activated in vitro by Cpg2216, releasing large amounts
of IFN-α (Figure 2C ) and upregulatingMHCII expression (Figure 2D).
Incubation with CpG2216 also increased the release of TNF-α and
IL-6 from pDCs in vitro (Figure 2C ).
We next aimed to assess whether tumor-infiltrating pDCs recruited
on Ad.TK + Ad.Flt3L treatment exhibited phagocytic activity within
the brain tumor microenvironment. The phagocytic activity of tumor-
infiltrating pDCs was evaluated in vivo in tumor-bearing rats treated with
Ad.TK/GCV + Ad.Flt3L using yellow-green beads that were injected
intratumorally 3 days after the treatment (Figure 3A). Our results indi-
cate that the beads were distributed throughout the brain tumor mass
(FigureW1A). Beadswere detected in the cytoplasm of tumor-infiltrating
OX-62+ cells (Figure 3B) and CD45R+/CD4+ cells (Figure 3C), suggest-
ing that both cDCs and pDCs exhibit phagocytic activity. Macrophages
containing beads were also readily found in the brain tumor micro-
environment (Figure W1B). Cells containing beads were also detected in
the cervical lymph nodes, some of which expressed CD45R and CD4,
which aremarkers for pDCs (Figure 3D), suggesting that they are capable
of trafficking to the dLNs where they could interact with naive T cells.
To assess whether tumor-infiltrating pDCs were able to prime T cells,
we performed an allogeneic mixed leukocyte reaction. Tumor-infiltrating
pDCs were collected from the brain 5 days after the treatment with
Ad.TK/GCV + Ad.Flt3L and incubated with T cells purified from the
spleen of allogeneic C57/BL6 mice and labeled with CFDA-SE
(Figure 4A). T-cell proliferation was determined by flow cytometry as
the decay in CFDA-SE fluorescence. We found that increasing con-
centrations of tumor-infiltrating pDCs stimulated the proliferation
of allogeneic T cells, suggesting that tumor-infiltrating pDCs are
capable of providing costimulatory signals that are required to support
T-cell proliferation.
pDCs Delivered into the Tumor Microenvironment Mimic
the Effect of Ad.Flt3L
Because we found that tumor-infiltrating pDCs were capable of
phagocytosis andT-cell priming, we next aimed to establish the relevance
of tumor-infiltrating pDCs in triggering the antitumor immune
response induced by Ad.TK + Ad.Flt3L. Therefore, we tested the
hypothesis that pDCs would mimic the effect of Ad.Flt3L when
administered intratumorally in combination with Ad.TK. To obtain
adequate numbers of pDCs for this experiment, naive rats were injected
intravenously with Ad.Flt3L, which expands the pDC population in
the bone marrow (from <0.5% to 3.5% of bone marrow leukocytes;
not shown). Two weeks later, bone marrow pDCs were purified by
FACS (CD3−/CD4+/CD45R+; Figure 4B) and incubated in the pres-
ence of CNS-1 cell lysates. These pulsed pDCs (150,000/rat) were
mixed with CpG 2216 immediately before intratumoral injection on
day 10 after tumor implantation. To avoid the infection of pDCs with
Ad.TK, rats received the injection of Ad.TK 24 hours before treatment
with pDCs (day 9 after tumor implantation). Whereas all the rats that
received Ad.TK or pDCs alone died because of tumor burden, com-
bined therapy with Ad.TK + pDCs led to tumor regression and
long-term survival in 35% of the rats (Figure 4C ). These findings
suggest that pDCs play an important role in mediating the antitumor
immune response induced by Ad.TK + Ad.Flt3L.
IFN-α Mediates the Therapeutic Effect of Ad.TK + Ad.Flt3L
Considering that the main cytokine secreted by pDCs is IFN-α, we
next aimed to elucidate whether the therapeutic efficacy of Ad.TK +
Ad.Flt3L was dependent on IFN-α. We constructed an Ad encod-
ing B16R (Ad.B18R), a type I interferon-binding protein that blocks
IFN-α function [31], under the control of the ubiquitous murine CMV
promoter (Figure W2). We first assessed the ability of Ad.B18R to
block the function of IFN-α in vitro (Figure 5A). COS7 cells were
infected with a vector expressing IFN-α (Ad.IFN-α) in the presence or
absence of increasing concentrations of Ad.B18R, and IFN-α levels were
assessed by a biologic assay using the pISRE plasmid, which encodes
an interferon-sensitive response element linked to firefly luciferase.
A plasmid encoding constitutive renilla luciferase was used as internal
control. We found that expression of B18R blocks the function of
IFN-α in a dose-dependentmanner, and thus we used Ad.B18R to block
the activity of IFN-α in vivo. Ten days after tumor implantation, rats
received an intratumoral injection of saline or Ad.TK + Ad.Flt3L
alone or in combination with Ad.B18R (Figure 5B). Treatment with
Ad.B18R led to complete failure of the immune therapy, suggesting
that the release of IFN-α is crucial to establish the antitumor immune
response triggered by Ad.TK + Ad.Flt3L.
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Figure 1. Quantification of tumor-infiltrating immune cells. A total of 5000 CNS-1 cells were implanted in the striatum of Lewis rats, and
10 days later, rats received an intratumoral injection of Ad.Flt3L + Ad.TK followed by daily administration of GCV or, as controls, saline or
an empty vector (Ad.0). At 5 and 12 days after the treatment, brain mononuclear cells were isolated from the brain tumors and analyzed
using flow cytometry. Note that because control rats die of tumor burden at days 17 to 20, they cannot be included in day 22 analysis.
*P < .05 versus saline. Kruskal-Wallis test followed by Dunn test.
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Figure 2. Activation markers and cytokine release in tumor-infiltrating pDCs. (A) Immune cells from CNS-1 tumors were collected 5 days
after treatment with Ad.TK + Ad.Flt3L and CD3−CD45R+CD4+ cells were purified by flow cytometric cell sorting. Cells were charac-
terized by expression of activation markers and cytokine release. (B) Expression of activation markers CD86 and MHC II was determined
by flow cytometry. Naive spleen pDCs incubated 24 hours with ODN CpG2216 were used as positive controls. (C) Cytokine release was
determined in tumor-infiltrating pDCs and naive spleen pDCs after incubation with ODN CpG2216 for 24 hours. IL-6 and TNF-α expres-
sions were detected by ELISA, and IFN-α expression was assessed by a biologic assay using the pISRE plasmid. *P < .05 versus me-
dium; ^P < .05 versus tumor pDCs. Two-way ANOVA followed by Student-Newman-Keuls test. (D) Columns represent the percentage
of pDCs expressing MHC II, as determined by immunofluorescence, after incubation with ODN CpG 2216 for 24 hours. Pictures in the
right show ODN CpG2216-induced MHC II expression in tumor-infiltrating pDCs (green). Cytoskeleton was stained with phalloidin–Alexa
594 (red). Nuclei were stained with DAPI.
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In view of the central role of IFN-α in the antitumor immunity trig-
gered by Ad.TK + Ad.Flt3L, we evaluated whether a vector encoding
IFN-α could also trigger antitumor immunity in this model. We first
assessed the efficacy of Ad.IFN-α in rats bearing small intracranial
CNS-1 tumors. We found that intratumoral administration of
Ad.IFN-α 4 days after tumor implantation led to long-term survival
in more than 50% of rats (Figure W3). However, when we treated rats
bearing larger tumors (day 10 after tumor implantation), we found that
Ad.IFN-α alone did not induce tumor regression (Figure 5C ). Con-
versely, when rats bearing large tumors were treated with a combination
of Ad.IFN-α and Ad.TK, more than 50% exhibited tumor regression
and long-term survival (Figure 5, C and D). Taken together, these
findings indicate that IFN-α plays a critical role in Ad.TK/Ad/Flt3L
mediated anti-GBM therapeutic efficacy.
Figure 3. Phagocytic activity by cDCs and pDCs. (A) Three days after treatment with Ad.TK + Ad.Flt3L tumor-bearing rats were injected
intratumorally with fluorescent microbeads. Two days later, the brains immune cells were detected by immunofluorescence. Bar, 15 μm.
(B) Confocal microphotograph showing tumor-infiltrating cells expressing the cDC marker OX62 (red) containing beads (white) in the
cytoplasm (indicated by arrows). (C) Confocal microphotograph showing tumor-infiltrating cells expressing the pDCmarkers CD45R (green)
and CD4 (red) and containing beads (white) in the cytoplasm (indicated by arrows). (C) Confocal microphotograph showing cells in the
cervical lymph nodes expressing the pDC markers CD45R (green) and CD4 (red) and containing beads (white) in the cytoplasm (indicated
by arrows). Nuclei were stained with DAPI (blue). Bar, 10 μm.
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Expression of IFN-α in the Normal Brain Parenchyma
Leads to Overt Toxicity
Considering that in the clinical scenario, gene therapy vectors are in-
jected into the tumor bed after surgical resection, it was important to
determine any putative toxicity toward the normal brain parenchyma.
Thus, we next assessed the safety of Ad.IFN-α alone or in combination
with Ad.TK in the brain of naive rats and compared it with Ad.Flt3L +
Ad.TK. Control rats received saline or Ad.0. Neuropathology was
assessed 7 and 60 days later. We found that controls and rats that re-
ceived Ad.TK alone did not exhibit signs of local toxicity. Tallying with
our previous results [14], injection of Ad.TK + Ad.Flt3L into the naive
rat brain did not affect the integrity of the brain and did not lead to
overt inflammation. We observed only a mild and transient infiltration
of inflammatory cells, similar to that induced by injection of Ad.0. In
contrast, rats that received Ad.IFN-α alone or in combination with
Ad.TK exhibited signs of severe local toxicity 7 days after the treatment,
including hemorrhages, necrosis, demyelinization, and inflammation
with profuse infiltration of immune cells (Figures 6 and W4). These
signs of neurotoxicity were irreversible with severe ventriculomegaly
and chronic local inflammation that were still evident 60 days after
Figure 4. pDCs are able to prime T cells and eradicate intracranial GBM. (A) Tumor-infiltrating pDCs were purified by FACS (CD3−,
CD45R+, CD4+) 5 days after the treatment with Ad.TK/GCV + Ad.Flt3L. The ability of tumor-infiltrating pDCs to stimulate T-cell prolif-
eration was assessed by an allogeneic mixed leukocyte reaction. Increasing concentrations of tumor-infiltrating pDCs (stimulators) were
incubated with 20,000 CFDA-SE–labeled T cells (responders) collected from the spleen of allogeneic C57/BL6 mice. T-cell proliferation
was determined by the reduction in CFDA-SE fluorescence, as assessed by FACS. Representative histograms show CFDA-SE–labeled
T cells incubated with increasing ratios of pDCs. (B) pDCs from the bone marrow of rats that were intravenously injected with Ad.Flt3L
14 days before were purified by FACS (CD3−/CD4+/CD45R+). Dot plots show the gates for cell collection. pDCs were then incubated in
the presence of CNS-1 cell debris (debris/pDCs ratio was 3:1) followed by activation with CpG 2216. (C) Kaplan-Meier curves showing the
survival of tumor-bearing rats treated with Ad.TK at day 8 after tumor implantation, followed by intratumoral injection of activated pDCs
24 hours later. Rats received GCV for 7 days. *P < .05 versus saline. Log-rank test.
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injection (Figure W5). Our findings suggest that, whereas intracranial
administration of Ad.TK + Ad.Flt3L in the brain is safe, administration
of Ad.IFN-α poses risks of neurotoxicity. Because IFN-α was readily
detected in the serum of the rats that received intracranial injections
of Ad.IFN-α (Figure 7A), we assessed whether they also exhibited signs
of systemic toxicity. Rats that received Ad.IFN-α alone or in combi-
nation with Ad.TK underwent an acute weight loss, which was more
pronounced 5 days after injection (Figure 7B).
Discussion
We previously observed that Flt3L recruits pDCs into the naive brain
parenchyma [22]. Considering that the role of pDCs in tumor im-
munology remains debated [23], we aimed to assess the role played by
pDCs in the antitumor immune response elicited by Ad.TK/GCV +
Ad.Flt3L.We found that the administration of Ad.TK/GCV+Ad.Flt3L
induced active recruitment of plasmacytoid DCs (pDCs) into the brain
tumor microenvironment, which were capable of in vivo phagocytosis,
IFN-α release, and T-cell priming. Whereas the presence of pDCs has
been observed in several types of solid tumors, including head and neck
cancer, ovarian cancer, and melanoma [37], pDCs seem to be absent
within the tumor mass of patients with GBM [38]. Tallying with this,
we did not observe pDCs in untreated CNS-1 GBM.Other populations
of APCs were readily detected in CNS-1 tumors, including macrophages
and cDCs. The profile of APC infiltration in CNS-1 tumors was similar
to that reported for humanGBM[38]. Although there is a predominance
of microglia/macrophages followed by cDCs in freshly isolated human
glioma specimens, very few pDCs can be detected [38]. A reduction in
the levels of circulating pDCs has also been reported in patients with
different types of malignant tumors, including GBM [39]. Levels of
pDCs are reduced in the blood of patients with GBM, prostate, and
breast cancer when compared to healthy donors, and there is a significant
increase of circulating immature CD11c+ cells that exhibit poor APC
capability and correlate with tumor growth [39].
We found that administration of Ad.TK + Ad.Flt3L induced a fast in-
crease in the infiltration of all APC populations in the brain tumor mass,
which could promote tumor antigen presentation. Because pDCs were
detected in the tumor mass only when rats were treated with Ad.TK +
Ad.Flt3L, they secrete high levels of IFN-α and are capable of T-cell
priming, we hypothesized that they could be playing an important
role in the antitumor immune response induced by this treatment
[14,19,35,40,41]. It has been proposed that cDCs and pDCs that accu-
mulate in solid tumors are tolerogenic [42,43] and have a diminished
capacity to respond to inflammatory stimuli like TLR9 agonist CpG
[37]. However, pDCs isolated from human tumor specimens exhibit
the ability to uptake antigen,migrate, andproduce proinflammatory cyto-
kines, namely, IL-12 and IFN-α, and their activation using TLR agonists
Figure 5. Role of IFN-α in mediating the efficacy of immunotherapy in rat intracranial GBM. (A) COS7 cells were infected with a vector
expressing IFN-α (Ad.IFN-α) in the presence or absence of Ad.B18R (100 infectious units [iu]/cell), an Ad vector encoding the neutralizing
type I interferon receptor B18R, which blocks endogenous IFN-α. IFN-α function was assessed by a biologic assay using the pISRE
plasmid. *P < .05 versus uninfected cells (white column); ^P < .05 versus Ad.IFN-α without Ad.B18R (red column). One-way ANOVA
followed by Student-Newman-Keuls test. (B) Ten days after tumor implantation, rats received intratumoral injections of saline or Ad.TK +
Ad.Flt3L alone or in combination with AdB18R, followed by daily administration of GCV for 7 days. *P < .05 versus saline; ^P < .05
versus Ad.TK + Ad.Flt3L + Ad-B18R. Mantel log-rank test. (C) Tumor-bearing rats were treated 9 days after tumor implantation by
intratumoral injection of saline or Ad.IFN-α alone or in combination with Ad.TK followed by daily GCV administration. *P < .05 versus
saline. Mantel log-rank test. (D) Images showing the neuropathology of a representative Ad.TK + Ad.IFN-α–treated survivor, as assessed
by Nissl staining and immunocytochemistry of TH, CD68 (macrophages/activated microglia), and CD8α (T cells). Arrows indicate the
scar left after tumor regression.
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seems to have clinical value in cancer patients [44].Here we observed that
glioma-infiltrating pDCs produced higher levels of inflammatory cyto-
kines on activation with CpG than did naive spleen pDCs. CpG activa-
tion also induced the expression of MHC II in tumor-infiltrating pDCs,
as well as in naive spleen pDCs. These findings indicate that tumor-
infiltrating pDCs recruited by Ad.TK + Ad.Flt3L treatment have an
intact response to TLR9 activation. Although the expression of activa-
tion markers was relatively low in tumor-infiltrating pDCs, we showed
that these cells exhibit phagocytic activity and are capable of T-cell prim-
ing. These findings indicate that tumor-infiltrating pDCs could play a
role as APCs in the antitumor immune response induced by Ad.TK +
Ad.Flt3L treatment.
It has been reported that tumor cells can inhibit pDC function through
the release of anti-inflammatory cytokines such as tumor growth factor β,
vascular endothelial growth factor, and IL-10 into the tumor micro-
environment, which would reduce the ability of tumor-infiltrating pDCs
to trigger antitumor immunity [37,44]. However, when we delivered
tumor lysate–loaded pDCs activated with CpG into the CNS-1 tumors
treated with Ad.TK, they elicited tumor regression in 35% of the rats,
whereas all the rats treated with Ad.TK alone died to tumor burden. Al-
though the pDCs used in our experiment were obtained from the bone
marrow of rats injected intravenously with Ad.Flt3L, the immune re-
sponse triggered seems to be tumor antigen specific rather than against
putative Ad antigens presented by pDCs. We have not assessed the pos-
sibility of Ad infection in the pDC population; however, it is unlikely
that Ad antigens trigger an immune response that eradicates tumor cells.
If the immune response were against Ad antigens presented by pDCs, it
would lead to the destruction of pDCs, preventing antitumor efficacy.
Also, administration of pDCs without treating the tumor with Ad.TK
did not induce tumor regression or improved survival because the rats
died of tumor burden at the same time that saline-treated control rats
did. Further, in previous publications, we did not detect evidence of
anti-Ad immunity in Ad-treated tumor-bearing animals [45], which
indicates that intracranial administration of these vectors does not stim-
ulate an anti-Ad immune response. Our findings agree with previous
reports that show that TLR9-activated pDCs can trigger an antitumor
immune response that involves the sequential activation of NK cells,
cDCs, and CD8 T cells and leads to the regression of experimental
Figure 6. Acute neurotoxicity after Ad.IFN-α injection in naive rat brain. Naive Lewis rats were injected with Ad.IFN-α or Ad.Flt3L in the
striatum in combination with Ad.TK. As controls, rats received saline or Ad.0. Rats treated with Ad.TK received GCV treatment daily.
Seven days after vector delivery, neuropathologic analysis of the brain was assessed by Nissl staining and immunocytochemistry using
antibodies against TH, MBP, MHC II, CD68 (macrophages/activated microglia), and CD8α (T cells). Scale bar, 2 mm.
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melanomas in mice [46]. It is possible that pDCs recruited into the brain
tumor mass upon treatment with Ad.TK + Ad.Flt3L undergo activation
in response to intracellular proinflammatory molecules released by dying
tumor cells [17]. We have previously shown that the efficacy of this
treatment is dependent on the release from tumor cells undergoing cell
death [14,17], of the DNA binding protein, high-mobility group box 1
(HMGB1), which acts as an endogenous TLR agonist [47,48].
HMGB1 activates TLR2 in cDCs [17]. Tallying with our findings using
pDCs (Figure 4C), intratumor administration of cDCs leads to eradica-
tion of intracranial GBM in approximately 40% of tumor-bearing ani-
mals [17], suggesting that both subtypes of DCs participate in antitumor
immunity induced by Ad-TK + Ad.Flt3L.
It has been previously shown that pDCs activation is required
for T-cell priming and is characterized by the up-regulation of co-
stimulatory molecules and the release of proinflammatory molecules,
such as IL-6, TNF-α, and IFN-α [49]. IFN-α released from pDCs
is an important immune mediator because it regulates the activation
of other immune cells, such as cDCs, NK cells, and T cells [27],
and shows direct antitumor and antiangiogenic activity [6]. Tumor-
infiltrating pDCs released high levels of basal and CpG-induced
IFN-α, which could be involved in the antitumor immune response
induced by our treatment. Indeed, our results using the IFN-α decoy
receptor B18R show that the efficacy of Ad.TK + Ad.Flt3L is depen-
dent on the release of IFN-α. This cytokine exhibits a robust direct
antitumor effect by inhibiting angiogenesis and tumor cell proliferation
and also stimulates the immune system to target and eradicate tumor
cells [6]. In our model, intratumoral delivery of IFN-α in combination
with Ad.TK led to the regression of established CNS-1 gliomas. These
findings are in agreement with previous reports that show that Ad-
mediated IFN-α delivery alone or in combination with intratumor
DC vaccines leads to regression of GL261 tumors in mice [50]. How-
ever, our data demonstrated that delivery of this cytokine into the nor-
mal brain parenchyma led to considerable local and systemic toxicity.
Rats that received Ad.IFN-α exhibited signs of acute neurotoxicity,
such as hemorrhages, necrosis, demyelinization, and inflammation,
which were irreversible, with severe ventriculomegaly and signs of
chronic local inflammation still evident 2 months later. Because gene
therapy vectors are injected into the tumor bed after surgical resection,
the toxicity of IFN-α toward the normal brain parenchyma reduces the
suitability of this cytokine for the treatment of GBM.
Alternative IFN-α delivery strategies for the treatment of GBM have
been attempted using bone marrow–derived monocytes that express
IFN-α [51]. Adoptive transfer of these monocytes led to regression
of experimental intracranial GBM. Although because of the tumor-
homing specificity of these monocytes, there were negligible systemic
IFN-α expression and toxicity [51], the authors did not assess the
putative neurotoxicity of the treatment, and considering that the tumors
were implanted in nude mice, it was not possible to assess immune-
mediated toxicities in this model. Thus, the data reported in this study
highlight the significance of performing in vivo toxicity studies before
clinical translation of powerful proinflammatory cytokines for brain
tumor therapeutics. Our results indicate that, although the immune
response triggered by Ad.TK + Ad.Flt3L is mediated by the release of
IFN-α, the treatment does not induce apparent neurologic or systemic
side effects [14]. When exogenous IFN-α is delivered into the brain,
the lack of physiological regulation of its inflammatory functions leads
to overt toxicity, limiting its therapeutic implementation. However,
when IFN-α is released from pDCs recruited into the brain tumor by
Ad.TK + Ad.Flt3L, it does not elicit local or systemic toxic effects.
Although our results indicate that pDCs participate in the antitumor
effect of Ad.TK/GCV + Ad.Flt3L through the production of IFN-α, it
is possible that they also play a role as APCs, priming the adaptive anti-
tumor immune response induced by this treatment. Tumor-infiltrating
pDCs supported T-cell proliferation and exhibited phagocytic ac-
tivity within the tumor microenvironment. Yellow-green beads that
were injected intratumorally were detected in the cytoplasm of tumor-
infiltrating CD45R+/CD4+ cells in vivo, indicating that pDCs exhibit
phagocytic activity. Cells expressing markers for pDCs were detected in
the cervical lymph nodes containing beads, suggesting that they are capa-
ble of trafficking to the dLNs where they could interact with naive T cells.
In summary, we observed that pDCs recruited into the tumor mass
on Ad.TK/GCV + Ad.Flt3L exhibit the ability to uptake and transport
fluorescent beads present within the tumor microenvironment, pro-
duce inflammatory cytokines, and support T-cell proliferation. Our
data indicate that IFN-α release by activated pDCs plays a critical role
in the antitumor immunity induced by Ad.TK/GCV +Ad.Flt3L. Thus,
manipulation of pDCs constitutes a novel target for the treatment of
brain cancer. In this regard, the in vitro expansion of pDCs can be
exploited in the development of antitumor vaccines [52]. pDC-based
vaccines have shown strong antitumor efficacy in mouse models of
cancer [53]. Importantly, these vaccines stimulate the intratumoral
infiltration of antigen-specific lymphocytes in patients with melanoma
[53]. The activation of immature tumor-infiltrating pDCs can also be
Figure 7. Weight loss after Ad.IFN-α injection in naive rat brain. (A)
Circulating levels of IFN-α were assessed by a biologic assay using
the pISRE plasmid in serum collected 7 days after Ad administration.
Recombinant rat IFN-α (rIFN-α, 1000 U/ml) was used as positive con-
trol. *P < .05 versus saline. One-way ANOVA followed by Student-
Newman-Keuls test. (B) Body weight was assessed daily in a group
of rats for 4 weeks. *P < .05 versus saline. Randomization test.
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achieved using TLR agonists [54]. Intratumor administration of the
TLR9 agonists, ODN CpGs, induces T cell–dependent antitumor
immunity, reducing the size of solid tumors, namely, lymphoma and
melanoma, implanted in mice [55]. Direct tumor injection of ODN
CpGs stimulates the regression of malignant skin neoplasms in human
patients [56]. Imiquimod, a synthetic TLR7 agonist, has also been
shown to induce the accumulation of pDCs and increase the production
of IFNs in skin malignancies [52]. These strategies could be useful
adjuvants to further enhance the activity of glioma-infiltrating pDCs
recruited by Ad.TK + Ad.Flt3L treatment.
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Figure W1. Bead internalization by ED1+ Iba1+ cells. Three days after treatment with Ad.TK + Ad.Flt3L, tumor-bearing rats were injected
intratumorally with fluorescent microbeads. Two days later, the brains’ immune cells were detected by immunofluorescence. (A) Arrows
pointing cells containing beadswithin the brain tumor. Broken line indicates tumor border. Inset shows high-magnificationmicrophotograph
of cells containing beads within the tumor mass. (B) Confocal microphotograph showing tumor-infiltrating cells expressing the macrophage
and microglia cell markers ED1 (red) and Iba1 (green) and containing beads (white) in the cytoplasm. Nuclei were stained with DAPI (blue).
Figure W2. Construction of Ad.B18R. Adenoviral shuttle plasmid pAL120-B18R encoding the Vaccinia virus B18R cDNA (orange) that
encodes a decoy receptor for IFN-α, which inhibits its function. Transgene expression is driven by the powerful murine cytomegalovirus
promoter (mCMV, blue). Important restriction sites are indicated. Agarose gel electrophoresis and restriction map analysis of pAL120-B18R
plasmid DNA to check for expected band sizes are shown. Lanes are as follows: lane 1, Hyladder 10 kb (Denville Scientific, Metuchen, NJ;
corresponding sizes are labeled to the right of the gel); lane 2, uncut; lane 3, HindIII; lane 4, HindIII + SpeI; lane 5, EcoRV; lane 6, EcoRV +
HindIII; lane 7, SalI; lane 8, hyperladder 1. The colored fragments correspond to the indicated fragments in the schematic of Ad-mCMV-B18R
vector genome linear depiction.
Figure W3. Efficacy of intratumoral injection of Ad.TK in combina-
tion with Ad.IFN-α. Tumor-bearing rats were treated 4 days after
tumor implantation by intratumoral injection of saline or Ad.IFN-α
or saline. *P < .05 versus saline. Mantel log-rank test.
Figure W4. Acute neurotoxicity after Ad.IFN-α injection in naive rat brain. Naive Lewis rats were injected in the striatum with Ad.IFN-α or
Ad.TK. Rats treated with Ad.TK received GCV treatment daily. Seven and 60 days after vector delivery, neuropathologic analysis of the
brain was assessed by Nissl staining and immunocytochemistry using antibodies against TH, MBP, MHC II, CD68 (macrophages/activated
microglia), and CD8α (T cells). Scale bar, 2 mm.
Figure W5. Chronic neuropathologic changes after Ad.IFN-α injection in naive rat brain. Naive Lewis rats were injected in the striatum with
Ad.IFN-α or Ad.Flt3L and Ad-TK. As controls, rats received saline or Ad.0. Rats treated with Ad-TK received GCV treatment daily. Sixty days
after vector delivery, neuropathologic analysis of the brain was assessed by Nissl staining and immunocytochemistry using antibodies
against TH, MBP, MHC II, CD68 (macrophages/activated microglia) and CD8α (T cells). Scale bar, 2 mm.
